Hanren Dai

Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial

Chunmeng Wang, Zhiqiang Wu, Yao Wang et al. · Clinical Cancer Research · 2016 · 328 citations

Life Sciences, Immunology, Oncology +17

CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial

Yao Wang, Meixia Chen, Zhiqiang Wu et al. · OncoImmunology · 2018 · 328 citations · Full text

Medicine, Hematology, Oncology +17

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

Hanren Dai, Zhiqiang Wu, Hejin Jia et al. · Journal of Hematology & Oncology · 2020 · 323 citations · Full text

Medicine, Immunology, Oncology +11

Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers

Kaichao Feng, Yang Liu, Yelei Guo et al. · Protein & Cell · 2017 · 316 citations · Full text

Medicine, Oncology, Pharmacology +17

Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix

Wenlong Zhang, Ling Liu, Huifang Su et al. · British Journal of Cancer · 2019 · 287 citations · Full text

Life Sciences, Immunology, Oncology +17